| 标题 |
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet 作者:Robert P. Giugliano; Terje R. Pedersen; Jeong-Gun Park; Gaetano Maria De Ferrari; Zbigniew Gaciong; et al 出版日期:2017-08-28 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)